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Development of novel more efﬁcient preventive vaccines against tuberculosis (TB) is crucial to achieve TB
eradication by 2050, one of the Millennium Development Goals (MDG) for the current century. MTBVAC
is the ﬁrst and only live attenuated vaccine based on a human isolate of Mycobacterium tuberculosis
developed as BCG-replacement strategy in newborns that has entered ﬁrst-in-human adult clinical trials.
In this work, we characterize the safety, immunogenicity and protective efﬁcacy of MTBVAC in a model of
newborn C57/BL6 mice. Our data clearly indicate that MTBVAC is safe for newborn mice, and does not
affect animal growth or organ development. In addition, MTBVAC-vaccinated mice at birth showed
enhanced immunogenicity and better protection against M. tuberculosis challenge in comparison with
BCG.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tuberculosis (TB) disease causes more than one million and a
half deaths per year and is one of the leading infectious diseases
affecting developing countries. Thus, development of new vaccines
able to prevent TB represents a global emergency [1].
The only vaccine against TB in use today, Bacille Calmette-
Guerin (BCG), is a live attenuated strain from a Mycobacterium
bovis strain isolated from cattle, and is worldwide administered at
birth. Despite its effectiveness in reducing the incidence of the
disseminated forms of TB in children, it is inconsistent in pre-
venting pulmonary TB, the most common form of the disease in
adolescents and adults, and responsible of TB transmission [2]. BCG
was developed a century ago by repeated subculture. The loss of the
RD1 region-the principal genetic basis for its attenuation-, encodes
a secretion system to export the major T-cell antigen complex/cina Preventiva y Salud Púb-
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Ltd. This is an open access article uvirulence factor ESAT-6/CFP-10 [3]. In addition, when compared to
clinical isolates of theMycobacterium tuberculosis complex, BCG has
more than one hundred genes deleted from its genome [4],
including important immunodominant antigen proteins which
contain a high proportion of epitopes recognized by HLA complex,
considered important in generating effective long-lasting immune
responses [5]. Some of these antigens are employed in different
subunit TB vaccines for use in BCG-vaccinated individuals,
currently in clinical trials [1].
MTBVAC is a live rationally-attenuated derivative of the
M. tuberculosis isolateMT103, which belongs to the Lineage 4 (Euro-
American), one of the most widespread lineages of M. tuberculosis
[6].MTBVAC contains two independent stable deletionmutations in
the virulence genes phoP and fadD26 without antibiotic resistance
marker, in accordance to the established in the Second Geneva
Consensus document for progressing new live mycobacterial vac-
cines to advanced clinical development [7]. PhoP is a transcription
factor that controls 2% of the genome of MTB including production
of immunomodulatory cell-wall lipids and ESAT-6 secretion [8].
Deletion of fadD26 leads to complete synthesis abrogation of the
virulence surface lipids phtioceroldimycocerosates (DIM) [9].
MTBVAC has been the ﬁrst and only live attenuated M. tuberculosis
vaccine approved to enter into clinical trials. A ﬁrst-in-humannder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Weight monitoring of C57/BL6 mice immunized at birth for safety evalua-
tion. Groups of at least twelve newborn C57/BL6 mice were vaccinated at birth with
MTBVAC, BCG or PBS. Four weeks post-birth, mice were divided by gender and weight
was monitored weekly. Data showed in the ﬁgure correspond to mice weighed at four
and seven weeks post-birth. A representative experiment of two is shown. Data in the
graphs are represented as mean ± SEM. Statistical analysis was done using a one-way
ANOVA test to compare different vaccination groups for each age and gender. No
statistical differences were found.
N. Aguilo et al. / Tuberculosis 96 (2016) 71e7472MTBVAC clinical trial was recently conducted successfully in
healthy adults in Lausanne (Switzerland) (NCT02013245) [10].
Newborn mice have been used in different works as a model to
measure safety, immunogenicity and protective efﬁcacy of BCG
alone or in combination with diverse boosting approaches [11].
Given that the preclinical development of MTBVAC to date was
generated in adult animal models with the objective to support the
ﬁrst-in-human adult Phase 1a safety and immunogenicity trial in
Lausanne, the present safety and immunogenicity study in
newborn mice is the ﬁrst to date conducted to support progress to
Phase 1b evaluation of MTBVAC in newborns.
2. Material and methods
All micewere kept under controlled conditions and observed for
any sign of disease. Experimental work was conducted in agree-
ment with European and national directives for protection of
experimental animals and with approval from the competent local
ethics committees.
For vaccinationwith lyophilized BCG Danish 1331 (Staten Serum
Institute SSI) or MTBVAC (manufactured by Biofabri, Spain),
approximately 5  106 colony-forming units (CFU) were recon-
stituted with 1 mL of reconstitution buffer. Groups of C57/BL6
newborn mice were vaccinated subcutaneously with 50 ml of
reconstituted vaccines (2.5  105 CFU) in the ﬁrst three days after
birth. Unvaccinated controls were inoculated with 50 ml of phos-
phate buffered saline (PBS).
2.1. Safety
During the next eight weeks following vaccination of the
newborn mice, different welfare-related parameters as weight
gain, social and individual behaviour and food and water con-
sumption were monitored. Eight weeks post-vaccination, animals
were sacriﬁced and the target organs (spleen, kidneys, testes,
ovaries, heart, lungs, liver and brain) were harvested, weighed and
ﬁxed in formaldehyde for haematoxylin-eosin staining and path-
ological evaluation. The experts in charge of the anatomopatho-
logical examinationwere blinded to the vaccine group origin of the
indicated organs.
2.2. Immunogenicity
For immunogenicity assessment, 106 splenocytes per experi-
mental point were incubated with puriﬁed-protein derivative
(PPD) (Statens Serum Institut, SSI) 10 mg/ml or recombinant Ag85B
(Lionex) 2 mg/ml in culture medium during 48 h. After incubation,
supernatant was separated from the cellular fraction by centrifu-
gation and IFNg concentration determined by ELISA using a speciﬁc
commercial kit (MabTech), and performed according to manufac-
turer instructions.
2.3. Protective efﬁcacy
Eight weeks post-vaccination, mice were intranasally chal-
lenged with 150 CFUMTB H37Rv in 40 ml of PBS. Bacterial load from
lungs was determined four weeks postechallenge by plating lung
homogenates on solid 7H11 agar medium supplemented with ADC
(Difco).
2.4. Statistical analysis
GraphPrism software was used for statistical analysis. For ex-
periments with two experimental groups, unpaired t-student test
was used. When three or more groups were compared, One-WayANOVA analysis with Bonferroni post-test was performed. Differ-
ences were considered signiﬁcant at p < 0.05.
3. Results and discussion
Despite the failure of the subunit vaccine MVA85A to improve
BCG efﬁcacy in an infant Phase 2b trial in South Africa, the clinical
trial paved the way for testing of new TB vaccines in infants [12].
Some authors have criticized that considering the MVA85A pre-
clinical data available the failure of this vaccine candidate was not
unexpected [13,14]. Thus a lesson to be learnt through the experi-
ence with MVA85A is the necessity to conduct rigorous preclinical
characterization of vaccine candidates in models mimicking as
much as possible the conditions planned for testing in the clinic.
Since MTBVAC was conceived as a BCG-replacement strategy,
newborns represent its main target population. Nevertheless, all
the preclinical studies performed up to date with MTBVAC, or its
prototype version SO2 [7], have been carried out in different adult
animal models, showing an excellent safety proﬁle in all preclinical
experiments performed [7,15]. Following the successful outcome of
the ﬁrst-in-human Phase 1a trial in healthy adults in Lausanne, we
conducted the present study of MTBVAC in a neonatal preclinical
model with the aim to support progress to clinical evaluation in
healthy newborn infants.
3.1. Safety evaluation
In the whole study, a total of 80 newborn mice were vaccinated
with MTBVAC with no mortality or disease-associated symptom-
atology. As shown in Figure 1, both male and female mice vacci-
nated with MTBVAC gained weight in a similar way when
compared to control BCG and unvaccinated groups. At eight weeks
post-birth, animals were euthanatized and pivotal organs were
harvested for further analysis. No signiﬁcant differences with
respect to organ weight were found in any of the organs studied
(Supplementary Table 1). In addition, an anatomopathological
blind analysis from the selected organs was performed. Our results
Figure 2. Immunogenicity conferred by vaccination at birth in C57/BL6 mice. Groups of six newborn C57/BL6 mice were vaccinated with MTBVAC, BCG or PBS. Immunogenicity was
studied at eight weeks post-birth. Animals were humanely sacriﬁced and a cellular suspension from spleen was obtained. Cells were stimulated with PPD (A) or Ag85B (B) for 48 h
and subsequently IFNg analysed in cell supernatant by ELISA. A representative experiment of two is shown. Data in the graphs are represented as mean ± SEM. One-way ANOVA test
with Bonferroni post analysis was performed to calculate statistical signiﬁcance. *p < 0.05; **p < 0.01; ***p < 0.001.
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of the studied organs. Thus, we conclude that MTBVAC did not
produce structural or developmental changes in any studied organ
in newborn immunized mice.
3.2. Immunogenicity evaluation
Newborn immunization takes placewhen the immune system is
still immature which may represent an important difference to
vaccination in adults. This fact could have an impact in the immune
response triggered by vaccination. Indeed, Phase 2b and otherFigure 3. Protective efﬁcacy conferred by vaccination at birth in C57/BL6mice. Groups of three
post-birth, animalswere challenged intranasallywithH37Rvand fourweeks later CFUswere det
ﬁgure. Data in the graphs are represented as mean ± SEM. One-way ANOVA test with Bonferro
***p < 0.001; ****p < 0.0001. P value shown in Experiment 2 (SPLEEN) graph, comparing BCG aMVA85A clinical studies have shown that Th1 responses induced
by this vaccine are weaker in infants compared to adults [12]. To
assess vaccine-induced immunogenicity with MTBVAC, we har-
vested splenocytes from eight-week-old mice vaccinated at birth
and stimulated ex vivo cells with PPD (Figure 2A) or single antigen
Ag85B (Figure 2B) for 48 h. We analysed next IFNg production by
ELISA. IFNg production was higher in the group of MTBVAC-
vaccinated mice after stimulation with PPD or Ag85B. PPD results
contrasted with those obtained in adult C57/BL6 mice, where non-
signiﬁcant differences between MTBVAC- and BCG-vaccinated an-
imals were found after PPD stimulation ([16], Unpublished results).to nine newborn C57/BL6micewere vaccinatedwithMTBVAC, BCG or PBS. At eight weeks
ermined in lungs (A) and spleen (B).Data of two independent experiments are shown in the
ni post analysis was performed to calculate statistical signiﬁcance. *p < 0.05; **p < 0.01;
nd MTBVAC groups, was determined using a ManneWhitney t-student test.
N. Aguilo et al. / Tuberculosis 96 (2016) 71e7474The results with Ag85B may be relevant, based on data with other
Ag85B-based vaccines showing improved protective efﬁcacy when
compared to BCG, suggesting that Ag85B-speciﬁc response could be
protective [17]. Ag85B is one of the most antigenic proteins of
M. tuberculosis, harbouring a number of experimentally conﬁrmed
human T cell epitopes. Importantly, a recent report showed that all
BCG strains contain a polymorphism in ag85b gene, which triggers
an amino acid substitution predicted to affect protein's structure
and stability [5].3.3. Protective efﬁcacy evaluation
To evaluate protective efﬁcacy, we intranasally inoculated eight-
week old mice vaccinated at birth with a low dose of H37Rv and
four weeks after challenge we determined bacterial load reduction
in lungs and spleen. A group of ten unvaccinated mice was sacri-
ﬁced one day after challenge to determine the initial number of
bacteria in lungs, resulting in a mean value ± SEM of 29 CFU ± 11.
The two independent experiments performed showed a similar
efﬁcacy proﬁle in lungs and spleen, and both BCG and MTBVAC
conferred signiﬁcant protection in comparison with unvaccinated
controls. Remarkably, bacterial reduction in lungs induced by
MTBVAC was signiﬁcantly higher (around 0.5 logs) than the
decrease triggered by BCG. In the case of bacterial load in spleen,
MTBVAC also tended to provide a better protection than BCG,
although no signiﬁcance was observed in this case (Figure 3).
Since BCG is effective in preventing disseminated TB in children
one of the potential issues of BCG-replacement TB vaccines is that
individuals in TB-endemic countries not vaccinated with BCG at
birth might be at risk of developing disseminated TB in childhood.
Given that MTBVAC is aimed for use at birth, our data provide ev-
idence for the adequate safety and improved immunogenicity and
protection efﬁcacy proﬁle as compared to licensed BCG Danish SSI,
suggesting that newborn vaccination with MTBVAC in clinic is ex-
pected to be at least as safe, immunogenic and effective as BCG.4. Conclusions
The most important conclusion of this study is that MTBVAC is
safe in newborn mice, and does not affect organ development. To
our knowledge, this is the ﬁrst time that a live attenuated
M. tuberculosis vaccine is tested in a preclinical neonatal model, so
this work can pave the way for the preclinical and clinical devel-
opment of other M. tuberculosis-based vaccines targeting this
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